Research programme: human plasma-derived biologics - Abeona Therapeutics
Alternative Names: A1PI - Abeona Therapeutics; AAT - Abeona Therapeutics; AHF - Abeona Therapeutics; Alpha-1 protease inhibitor - Abeona Therapeutics; Antihaemophilic factor VIII - Abeona Therapeutics; Coagulation factors - Abeona Therapeutics; Human plasma-derived therapeutics - Abeona Therapeutics; IVIG - Abeona Therapeutics; Protein biologic therapeutics - Abeona Therapeutics; PTB-101 SDF Alpha™; PTB-201 SDF IVIG™; SDF Alpha™; SDF Gamma™Latest Information Update: 24 May 2018
Price :
$50 *
At a glance
- Originator PlasmaTech Biopharmaceuticals
- Developer Abeona Therapeutics
- Class Acute-phase proteins; Alpha globulins; Blood coagulation factors; Blood proteins; Enzymes; Glycoproteins; Immunoglobulins; Immunoproteins; Secretory proteinase inhibitory proteins; Serum globulins
- Mechanism of Action Alpha 1-antitrypsin replacements; Factor VIII stimulants; Immunoglobulin stimulants; Immunomodulators; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency; Autoimmune disorders; Blood coagulation disorders; Chronic obstructive pulmonary disease; Haemophilia A; Immunocompromised infections
Most Recent Events
- 24 May 2018 Discontinued - Preclinical for Autoimmune disorders in USA (IV)
- 24 May 2018 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (Parenteral)
- 24 May 2018 Discontinued - Preclinical for Immunocompromised infections in USA (IV)